JP2018521999A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521999A5 JP2018521999A5 JP2017568205A JP2017568205A JP2018521999A5 JP 2018521999 A5 JP2018521999 A5 JP 2018521999A5 JP 2017568205 A JP2017568205 A JP 2017568205A JP 2017568205 A JP2017568205 A JP 2017568205A JP 2018521999 A5 JP2018521999 A5 JP 2018521999A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- fusion protein
- hvem
- mutation
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021083133A JP2021113240A (ja) | 2015-06-30 | 2021-05-17 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2022115473A JP7559013B2 (ja) | 2015-06-30 | 2022-07-20 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2023210069A JP2024019529A (ja) | 2015-06-30 | 2023-12-13 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187105P | 2015-06-30 | 2015-06-30 | |
| US62/187,105 | 2015-06-30 | ||
| PCT/US2016/040108 WO2017004213A1 (en) | 2015-06-30 | 2016-06-29 | Btla fusion protein agonists and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083133A Division JP2021113240A (ja) | 2015-06-30 | 2021-05-17 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521999A JP2018521999A (ja) | 2018-08-09 |
| JP2018521999A5 true JP2018521999A5 (enExample) | 2019-06-06 |
| JP7116285B2 JP7116285B2 (ja) | 2022-08-10 |
Family
ID=57609132
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568205A Active JP7116285B2 (ja) | 2015-06-30 | 2016-06-29 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2021083133A Pending JP2021113240A (ja) | 2015-06-30 | 2021-05-17 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2022115473A Active JP7559013B2 (ja) | 2015-06-30 | 2022-07-20 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2023210069A Pending JP2024019529A (ja) | 2015-06-30 | 2023-12-13 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083133A Pending JP2021113240A (ja) | 2015-06-30 | 2021-05-17 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2022115473A Active JP7559013B2 (ja) | 2015-06-30 | 2022-07-20 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2023210069A Pending JP2024019529A (ja) | 2015-06-30 | 2023-12-13 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10961297B2 (enExample) |
| EP (1) | EP3317297A4 (enExample) |
| JP (4) | JP7116285B2 (enExample) |
| KR (2) | KR20240110000A (enExample) |
| CN (2) | CN114853903A (enExample) |
| AU (3) | AU2016286108B2 (enExample) |
| BR (1) | BR112017028316A2 (enExample) |
| CA (1) | CA2990885A1 (enExample) |
| EA (1) | EA201890171A1 (enExample) |
| IL (2) | IL256383B2 (enExample) |
| MX (1) | MX2018000073A (enExample) |
| SG (1) | SG10201913567QA (enExample) |
| WO (1) | WO2017004213A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3247728T (pt) | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| AU2016286108B2 (en) | 2015-06-30 | 2021-03-11 | Pfizer Inc. | BTLA fusion protein agonists and uses thereof |
| GB201820554D0 (en) | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| GB202008860D0 (en) | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| AU2023212896A1 (en) * | 2022-01-29 | 2024-08-22 | Hifibio, Inc. | Antibody against btla and uses thereof |
| WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291207B1 (en) * | 1995-07-28 | 2001-09-18 | Northwestern University | Herpes virus entry receptor protein |
| TR200504220T2 (tr) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
| WO2007001459A2 (en) | 2004-11-15 | 2007-01-04 | Washington University | Compositions and methods for modulating lymphocyte activity |
| US8546541B2 (en) | 2002-06-20 | 2013-10-01 | Washington University | Compositions and methods for modulating lymphocyte activity |
| US20030235580A1 (en) | 2002-06-24 | 2003-12-25 | Fen Zhang | Amniotic membrane mediated delivery of bioactive molecules |
| US7153950B2 (en) | 2002-10-25 | 2006-12-26 | Genentech, Inc. | Nucleic acids encoding an immune related polypeptide |
| EP1812465B1 (en) | 2004-11-12 | 2016-09-07 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| WO2010006071A1 (en) * | 2008-07-08 | 2010-01-14 | La Jolla Institute For Allergy And Immunology | Hvem/btla, hvem/cd160 and hvem/gd cis complexes and methods of use |
| EP1833848A2 (en) | 2004-12-09 | 2007-09-19 | Lajolla Institute for Allergy and Immunology | Novel tnf receptor regulatory domain |
| US8349320B2 (en) * | 2004-12-09 | 2013-01-08 | La Jolla Institute For Allergy And Immunology | Compositions and methods for modulating responses mediated or associated with BTLA activity |
| WO2007010692A1 (ja) | 2005-07-19 | 2007-01-25 | Japan Science And Technology Agency | Ｈｖｅｍ及びｂｔｌａを標的とした炎症性腸疾患治療用医薬組成物及び治療方法 |
| MX2009005189A (es) | 2006-11-15 | 2009-06-30 | Medarex Inc | Anticuerpos humanos monoclonales para btla y metodos de uso. |
| US8318662B2 (en) | 2009-03-16 | 2012-11-27 | Korea Institute Of Radiological & Medical Sciences | Protein increasing cell infectivity of herpes simplex virus and use thereof |
| US8303952B2 (en) | 2009-06-08 | 2012-11-06 | Washington University | Methods for inducing in vivo tolerance |
| CA2769473A1 (en) * | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
| US9982023B2 (en) | 2011-11-15 | 2018-05-29 | Sanford-Burnham Medical Research Institute | Compositions and methods for treating autoimmune and inflammatory disorders |
| JP2016530298A (ja) | 2013-09-05 | 2016-09-29 | サンフォード−バーンハム メディカル リサーチ インスティテュート | γδＴ細胞の調節 |
| KR20170134525A (ko) | 2015-04-02 | 2017-12-06 | 메모리얼 슬로안-케터링 캔서 센터 | Tnfrsf14 / hvem 단백질 및 이의 이용 방법 |
| EP3288587A4 (en) | 2015-04-29 | 2018-09-12 | Sanford-Burnham Medical Research Institute | Modulation of immune response using btla agonist antibodies |
| AU2016286108B2 (en) | 2015-06-30 | 2021-03-11 | Pfizer Inc. | BTLA fusion protein agonists and uses thereof |
| CA3013333A1 (en) | 2016-02-26 | 2017-08-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity for btla and uses thereof |
| US12145993B2 (en) | 2016-06-08 | 2024-11-19 | Shanghai Jiao Tong University School Of Medicine | Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity |
| US12281339B2 (en) | 2016-07-05 | 2025-04-22 | Polaris Group | Combination cancer immunotherapies with arginine depletion agents |
| US12447213B2 (en) | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| US20200140547A1 (en) | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| AU2018355487B2 (en) | 2017-10-27 | 2023-09-21 | Shanghai Yao Yuan Biotechnology Co., Ltd. | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 |
| WO2019094559A2 (en) | 2017-11-09 | 2019-05-16 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
| CR20200566A (es) | 2018-05-25 | 2021-02-19 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilización de los mismos |
| JP7097465B2 (ja) | 2018-06-19 | 2022-07-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | キメラ抗原受容体細胞療法と併用するｉｌ－１０剤の組成およびその使用方法 |
| AU2019293589A1 (en) | 2018-06-29 | 2021-01-21 | Alector Llc | Anti-SIRP-beta1 antibodies and methods of use thereof |
| WO2020041361A1 (en) | 2018-08-20 | 2020-02-27 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
| CA3109563A1 (en) | 2018-09-14 | 2020-03-19 | Universite De Lausanne | Methods for modulating regulatory t cells and inhibiting tumor growth |
| EP3880711A4 (en) | 2018-11-15 | 2022-12-28 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
-
2016
- 2016-06-29 AU AU2016286108A patent/AU2016286108B2/en active Active
- 2016-06-29 CN CN202210348320.0A patent/CN114853903A/zh active Pending
- 2016-06-29 SG SG10201913567QA patent/SG10201913567QA/en unknown
- 2016-06-29 EP EP16818691.4A patent/EP3317297A4/en active Pending
- 2016-06-29 US US15/737,259 patent/US10961297B2/en active Active
- 2016-06-29 IL IL256383A patent/IL256383B2/en unknown
- 2016-06-29 IL IL297395A patent/IL297395B2/en unknown
- 2016-06-29 BR BR112017028316-6A patent/BR112017028316A2/en active Search and Examination
- 2016-06-29 WO PCT/US2016/040108 patent/WO2017004213A1/en not_active Ceased
- 2016-06-29 EA EA201890171A patent/EA201890171A1/ru unknown
- 2016-06-29 JP JP2017568205A patent/JP7116285B2/ja active Active
- 2016-06-29 MX MX2018000073A patent/MX2018000073A/es unknown
- 2016-06-29 CA CA2990885A patent/CA2990885A1/en active Pending
- 2016-06-29 KR KR1020247017225A patent/KR20240110000A/ko active Pending
- 2016-06-29 CN CN201680049768.5A patent/CN108026159B9/zh active Active
- 2016-06-29 KR KR1020187002960A patent/KR102669985B1/ko active Active
-
2021
- 2021-03-01 US US17/188,912 patent/US11939367B2/en active Active
- 2021-05-17 JP JP2021083133A patent/JP2021113240A/ja active Pending
- 2021-06-08 AU AU2021203768A patent/AU2021203768B2/en active Active
-
2022
- 2022-07-20 JP JP2022115473A patent/JP7559013B2/ja active Active
-
2023
- 2023-04-14 AU AU2023202302A patent/AU2023202302A1/en not_active Abandoned
- 2023-12-13 JP JP2023210069A patent/JP2024019529A/ja active Pending
-
2024
- 2024-02-15 US US18/442,988 patent/US20240247047A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7746499B2 (ja) | Ｃｌｅｃ９ａ結合物質およびその使用 | |
| JP7605800B2 (ja) | 標的化キメラタンパク質及びその使用 | |
| CN111328286B (zh) | Pd-1和pd-l1结合剂 | |
| US20240247047A1 (en) | BTLA Fusion Protein Agonists and Uses Thereof | |
| JP2020505955A (ja) | 標的化改変型インターフェロン及びその使用 | |
| JP2017533207A5 (enExample) | ||
| US20250320302A1 (en) | Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection | |
| HK40074138A (en) | Anti-tim3 monoclonal antibodies and chimeric antigen receptors | |
| HRP20210383T1 (hr) | Kombinirana terapija za rak | |
| Branschädel | Analysis of molecular components essential for the formation of signaling-competent TNF-TNFR complexes |